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annotated baseline phenotypes
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Richard Keen7, Mona Al Mukaddam8, Kim-Hanh Le Quan Sang2, Amy Wilson9, Barbara White9,
Donna R. Grogan9 and Frederick S. Kaplan10*Abstract
Background: Fibrodysplasia Ossificans Progressiva (FOP; OMIM#135100) is an ultra-rare, severely disabling genetic
disease characterized by congenital malformation of the great toes and progressive heterotopic ossification (HO) in
muscles, tendons, ligaments, fascia, and aponeuroses often preceded by painful, recurrent soft tissue swelling
(flare-ups). The formation of HO leads to progressive disability, severe functional limitations in joint mobility,
and to a shortened life-span. In this prospective natural history study, we describe the baseline, cross-sectional
disease phenotype of 114 individuals with FOP.
Methods: All subjects underwent protocol-specified baseline assessments to determine their disease status. Cross-
sectional analyses were performed using linear regression in which functional evaluations (Cumulative Analogue Joint
Involvement Scale [CAJIS] and the FOP-Physical Function Questionnaire [FOP-PFQ]) and the burden of HO as measured
by low-dose whole body CT (volume of HO and number of body regions with HO) were assessed.
Results: Findings from 114 subjects (age range 4 to 56 years) were evaluated. While subject age was significantly
(p < 0.0001) correlated with increased CAJIS (r = 0.66) and FOP-PFQ scores (r = 0.41), the estimated mean increases per
year (based on cross-sectional average changes over time) were small (0.47 units and 1.2%, respectively). There was also
a significant (p < 0.0001) correlation between baseline age and HO volume (r = 0.56), with an estimated mean increase
of 25,574mm3/year. There were significant (p < 0.0001) correlations between the objective assessment of HO volume
and clinical assessments of CAJIS (r = 0.57) and FOP-PFQ (r = 0.52).
Conclusions: Based on the cross-sectional analysis of the baseline data, functional and physical disability as assessed by
CAJIS and the FOP-PFQ increased over time. Although longitudinal data are not yet available, the cross-sectional analyses
suggest that CAJIS and FOP-PFQ are not sensitive to detect substantial progression over a 1- to 2-year period. Future
evaluation of longitudinal data will test this hypothesis. The statistically significant correlations between HO volume and
the functional endpoints, and the estimated average annual increase in total HO volume, suggest that the formation of
new HO will be measurable over the relative short-term course of a clinical trial, and represents an endpoint that is
clinically meaningful to patients.
Trial registration: This study (NCT02322255) was first posted on 23 December, 2014.
Keywords: Fibrodysplasia Ossificans Progressiva, Heterotopic ossification, Disease progression, Natural history, Clinical trial
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Fibrodysplasia Ossificans Progressiva (FOP) (OMIM
#135100) is a rare, severely disabling disease character-
ized by malformed big toes and progressive heterotopic
ossification (HO) in muscles, tendons, and ligaments,
and is often associated with painful, recurrent episodes
of soft tissue swelling (flare-ups). FOP is caused by a
recurrent heterozygous activating mutation of activin re-
ceptor A type I (ACVR1), a bone morphogenetic protein
(BMP) type I receptor [1, 2]. There are approximately
800 confirmed cases of FOP globally [3] with an estimated
prevalence of 0.6–1.3 per million individuals [4–6]. No
available therapies have been demonstrated to prevent the
formation of HO. Palliative treatment to alleviate symp-
toms is the current standard of care [7].
A classic feature of FOP is the formation of HO, often
in the context of patient-reported flare-up symptoms of
unpredictable frequency, duration, and location. Disease
progression is also reported in the absence of flare-ups
[8]. It is well recognized that recurrent episodes of HO
formation starting in childhood lead to cumulative dis-
ability and functional limitations over the disease course,
as well as to a shortened life span [9]. These insights
into the natural history of FOP are derived from pub-
lished case series [9–12] and a comprehensive global
survey of 500 patients with FOP [8]. Unlike in earlier
studies, all participants enrolled in this natural history
study (NHS) of FOP had prospective, protocol-specified
assessments of their disease at pre-specified time points.
This report describes the key design features of the
NHS and the analysis of baseline cross-sectional data
that describe the disease phenotype and potential end-
points with which to evaluate therapeutic candidates.
Methods
The NHS is an on-going prospective, longitudinal, glo-
bal, non-interventional study of male and female sub-
jects clinically diagnosed with FOP due to the ACVR1
R206H mutation. The study is being conducted at seven
international clinical sites (Buenos Aires, Argentina;
Woolloongabba, Australia; Paris, France; Genoa, Italy;
Stanmore, United Kingdom; Philadelphia, Pennsylvania,
United States; and San Francisco, California, United
States). Subjects are informed about the study through
international and local patient organizations, direct
physician outreach, and through postings on Clinical-
trials.gov and other similar websites.
The enrollment period began in December 2014 and
ended in December 2016. The end of the planned
36-month follow-up for all subjects is expected in
December 2019. All study sites obtained approval from
their local institutional review boards and complied with
all applicable national, local, ethical, and regulatory
guidelines. All subjects, or minor subjects’ parents/legalguardians, were required to provide written informed
consent. Age-appropriate assent was also obtained per local
regulations. The study is registered on Clinicaltrials.gov
(NCT02322255) and is sponsored by Clementia Pharma-
ceuticals Inc.
Objectives
There are three overall objectives in the NHS: (1) describe
the baseline FOP disease characteristics in order to iden-
tify clinically meaningful variables of disease progression
that may serve as appropriate endpoints with which to
assess the effectiveness of potential disease-modifying
therapeutics; (2) measure FOP disease progression over
36months of observation; and (3) systematically evaluate
flare-up outcomes. This report describes the baseline data
that support the first objective. Subsequent reports will
present the results that support the latter objectives, when
those data become available.
Subject population and eligibility
Males and females from birth through 65 years of age,
clinically diagnosed with FOP, and with verified ACVR1
R206H mutation (via centralized laboratory) were eli-
gible for inclusion.
Study design and timing of assessments
After screening and determination of eligibility, all sub-
jects underwent a thorough baseline examination, in-
cluding whole body computed tomography (WBCT)
imaging, to determine their current disease status. The
planned routine assessments over the 36-month obser-
vation period are shown in Table 1.
Endpoints
After screening and determination of eligibility, key end-
points were evaluated in all subjects to determine their
baseline disease status.
Demographics (age, sex) and baseline flare-up charac-
teristics (age at first flare-up, time since last flare-up,
and number of flare-ups in the past 12 months) were re-
ported. Blood and urine were also obtained for analysis
of clinical laboratory parameters and potential biomarker
activity (specific analytes are listed in Table 1).
The total body burden of HO was assessed by low
dose WBCT, excluding the head. WBCT scout views
were acquired in coronal and sagittal planes. WBCT
scans were acquired in the cranio-caudal direction from
the base of the skull through the feet using 3-mm axial
slices with 512 × 512 matrix and pitch of one. Bone and
soft-tissue kernels were utilized and coronal and sagittal
reconstructions were generated. A single independent
musculoskeletal radiologist at a central imaging labora-
tory used standardized procedures to review all baseline
WBCT images to determine the presence/absence of
Table 1 Timing of standard assessments over the 3-year study
Assessment/Procedure Screening/Baseline First 3 weeks Every 3 months Every 6 months Every 12 months
Clinic visit X X
Telephone contact X X X
Informed consent/assent X
Assess for eligibility X
Medical and FOP history X
Prior/concomitant medications X X X X X
Post-baseline medical events X X
Physical examination X X
Linear height (≥ 18 years old) X X
Knee and sitting height (< 18 years old) X X
Body weight X X
Vital signs X X
Electrocardiogram X X
Pulmonary function tests X X
Pulse oximetry X X
Clinical laboratory assessmentsa X X
Blood and urine for biomarkers samplesb X X
CAJIS X X
Knee and hand/wrist x-rays (< 18 years old) X
WBCT (excluding head) X X
FOP assistive devices assessment X X X
FOP-PFQ assessment X X X
PROMIS Global Scales X X X
Columbia-Suicide Severity Rating Scale X X
Genotyping X
Adverse events X X X X
aIncludes triglycerides, alanine aminotransferase, aspartate aminotransferase, amylase, total cholesterol, lipase, total bilirubin, alkaline phosphatase, hemoglobin,
hematocrit, platelets, and white blood cell count
bBone and cartilage biomarkers include osteocalcin, bone specific alkaline phosphatase, P1CP-C-terminal propeptide of type 1 procollagen, P1NP N-terminal
propeptide of type 1 procollagen, cartilage-derived retinoic acid-sensitive protein, and c-terminal telopeptide. The angiogenesis biomarker was urinary basic
fibroblast growth factor. The inflammation biomarkers included erythrocyte sedimentation rate, c-reactive protein, interleukin-6, interleukin-1 beta, tumor necrosis
factor-alpha, creatinine phosphokinase, and lactate dehydrogenase
Abbreviations: CAJIS = Cumulative Analogue Joint Involvement Scale, FOP = Fibrodysplasia Ossificans Progressiva, FOP-PFQ = Fibrodysplasia Ossificans Progressiva-
Patient Function Questionnaire, PROMIS = Patient-Reported Outcome Measure Information System, WBCT = whole body computed tomography
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upper spine/chest; and left and right shoulders, elbows,
wrists, hips, knees, and ankles). To determine total HO
volume, HO was segmented on each axial slice using
semi-automated seed growing and shrink wrap segmen-
tation algorithms whenever possible. When not possible,
manual contouring and nudging steps (Alice v9.0, PAR-
EXEL Informatics, Waltham, MA) were used to optimize
the HO segmentations as needed by the radiologist. The
HO volumes were calculated separately for each of the
15 body regions and summed for the whole body burden
of HO volume.
Range of motion across 12 joints (left and right shoulders,
elbows, wrists, hips, knees, and ankles) and three body re-
gions (jaw, cervical spine [neck], and thoraco-lumbar spine)was assessed using the Cumulative Analogue Joint Involve-
ment Scale (CAJIS) for FOP [13]. Each joint/region was
noted as: 0 = uninvolved; 1 = partially involved; 2 = com-
pletely ankylosed. Total scores ranged from 0 to 30, with
higher scores indicating more severe limitations in mobility
and function.
Physical function by subject report was assessed using
the FOP-Physical Function Questionnaire (PFQ), a
disease-specific instrument developed on the principles
outlined in the FDA Guidance for Industry, “Patient-
Reported Outcome Measures: Use in Medical Product
Development to Support Labeling Claims” [14]. The
instrument includes questions related to activities of
daily living and physical functioning. Age-appropriate
forms of the FOP-PFQ were completed by adults
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(subjects 14 years of age and younger). Because the total
scores vary by age across the FOP-PFQ instruments, the
analysis was performed on transformed scores expressed
as a percentage of the worst possible score with lower per-
centages indication worse functioning.
Physical and mental health were assessed using the
Patient Reported Outcome Measure Information System
(PROMIS) Global Physical and Global Mental Health
Scales for subjects 15 years and older [15], and the PROMIS
Pediatric Global Health Scale (proxy- and/or self-
completed forms) for subjects 14 years of age and younger
[16]. Scores were converted to T-scores such that a value of
50 (with a standard deviation of 10) represents the average
for the general population in the United States. Higher
T-scores indicate better physical/mental health.
Statistical analysis
Sample size
The sample size, which was based on enrollment projec-
tions throughout the global FOP community and not on
statistical justifications, was set at up to 100 subjects
(noting that subjects could be replaced at the discretion
of the sponsor should they withdraw for any reason),
with at least 10 subjects in each of the following categor-
ies: < 8 years old, 8 to < 15 years old, 15 to < 25 years old,
and 25 to ≤65 years old. These age categories were chosen
to obtain a representative cross-section of disease sever-
ity/progression.
Planned analyses
The cross-sectional analysis of baseline data from all
enrolled subjects was performed after the last subject was
enrolled into the study. Data were tabulated descriptively
(number and percentage of subjects for categorical param-
eters, and the number, mean, standard deviation, and
range for continuous parameters) overall and by age cat-
egory. The estimated cross-sectional difference over age in
functional outcomes (FOP-PFQ and CAJIS) and the total
body burden of HO as assessed by WBCT (volume of HO
and number of body regions with HO) was assessed using
linear regression with baseline age as the only covariate.
Similarly, correlations between functional outcomes and
the total body burden of HO were estimated with linear
regression with measures of total body burden of HO as
the only covariate. In focusing on one time point for each
subject, these cross-sectional analyses do not take into ac-
count the episodic and variable nature of FOP progres-
sion. Correction for multiple testing was not performed.
Results
Demographics and baseline disease
The two sites in the United States enrolled the most
subjects (22 [19%] in Philadelphia, PA; and 20 [18%] inSan Francisco, CA), followed by Argentina (20 [18%]
subjects), United Kingdom (17 [15%] subjects), France
(15 [13%] subjects), Italy (14 [12%] subjects), and
Australia (6 [5%] subjects).
Of the 117 subjects screened, 114 (97%) were docu-
mented to have the ACVR1 R206H mutation (two had
variants and one did not have FOP; these subjects were
not eligible for enrollment). The demographics and base-
line disease characteristics of these 114 subjects (from
24 countries) are shown in Table 2.
There was similar representation across the age categor-
ies (14.9% in the < 8 years group, 31.6% in the 8 to < 15
years group, 29.8% in the 15 to < 25 years group, 23.7% in
the ≥25 to ≤65 years group). The mean age of subjects was
17.6 years (ranging from 4 to 56 years; median 15 years),
with a slightly higher percentage of males (54.4%) than
females (45.6%).
Retrospective report of flare-ups within the preceding
12months tended to be greater in younger than in older
subjects: the mean number of flare-ups reported in the
previous 12months was highest in the 8 to < 15 years
group (6.8/year; median of 2.0/year) and lowest in the
oldest group (1.9/year; median of 1.0/year); and the aver-
age time since a subject’s prior flare-up was 0.7 years
(median of 0.3 years) in the youngest group compared
with 2.3 years (median of 0.9 years) in the oldest group.
In general, mean baseline clinical laboratory and bio-
marker analytes were within the normal range for each
age category.
Functional limitations, as assessed by the CAJIS and
FOP-PFQ were worse in older than in younger subjects.
Adult assessments of physical (PROMIS Global Physical
Health) and mental (PROMIS Global Mental Health
Scale) health were similar between the two older age cat-
egories. Children’s health as assessed by parent proxies
on the PROMIS Global Health Scale was worse in older
children than in younger children. The results are sum-
marized in Table 2.
While the total body volume of HO was variable
across the age groups (ranging from 0 to 2,833,946mm3;
Table 2), the median volume was lowest (21,692 mm3) in
the youngest subjects and highest (481,524 mm3) in the
oldest. The mean number of body regions with HO also
increased with age, varying from 3.1 regions in the youn-
gest age group to 8.8 regions in the oldest age group.
Functional disability progresses as subjects age
Subject age was strongly correlated with CAJIS, and
moderately correlated with the FOP-PFQ (Fig. 1), indi-
cating that functional disability in FOP advances over
time. The estimated average increases per year based on
a linear regression model (0.47 units [95% CI: 0.37–0.57]
for CAJIS and 1.2% [95% CI: 0.6–1.7%] for the FOP-PFQ)
were relatively small for both assessments.
Table 2 Demographics and baseline disease by age category
< 8 Yrs
(N = 17)
8 to < 15 Yrs
(N = 36)
15 to < 25 Yrs
(N = 34)
≥ 25 to≤ 65 Yrs
(N = 27)
Total
(N = 114)
Males, n (%) 9 (52.9) 24 (66.7) 16 (47.1) 13 (48.1) 62 (54.4)
Age (years)
Mean ± SD 5.9 ± 1.1 11.4 ± 2.1 18.9 ± 3.1 31.7 ± 6.7 17.6 ± 9.7
Median (min, max) 6.0 (4, 7) 11.0 (8, 14) 18.5 (15, 24) 30.0 (25, 56) 15.0 (4, 56)
Age at 1st flare-up
Mean ± SD 2.9 ± 2.1 4.4 ± 3.6 5.6 ± 4.8 7.1 ± 5.0 5.2 ± 4.4
Median (min, max) 2.0 (1, 6) 4.0 (0, 13) 3.5 (0, 17) 5.0 (0, 20) 4.0 (0, 20)
Years since last flare-up
Mean ± SD 0.7 ± 0.9 1.5 ± 2.8 1.5 ± 1.9 2.3 ± 3.5 1.6 ± 2.6
Median (min, max) 0.3 (0, 3) 0.5 (0, 14) 0.7 (0, 7) 0.9 (0, 15) 0.5 (0, 15)
Number of flare-ups in the past 12 months
Mean ± SD 2.9 ± 2.6 6.8 ± 11.2 2.2 ± 1.8 1.9 ± 1.6 3.8 ± 6.9
Median (min, max) 2.0 (1, 10) 2.0 (1, 40) 1.0 (1, 8) 1.0 (1, 7) 2.0 (1, 40)
CAJIS total scorea
Mean ± SD 5.6 ± 3.9 9.2 ± 4.6 13.9 ± 6.7 16.5 ± 7.3 11.8 ± 7.0
Median (min, max) 6.0 (1, 15) 8.5 (1, 20) 13.5 (1, 26) 18.0 (1, 30) 10.5 (1, 30)
FOP-PFQ % worst total scoreb
Mean ± SD 34.8 ± 26.1 44.4 ± 20.2 43.1 ± 31.0 58.4 ± 35.8 46.3 ± 27.1
Median (min, max) 41.8 (1, 84.6) 45.2 (1.9, 82.7) 38.4 (0, 100) 54.5 (0, 100) 45.5 (0, 100)
PROMIS Global Physical Health (adult) or PROMIS Global Health (pediatric, parent proxy) (T-score)c
Mean ± SD 47.6 ± 9.4 41.8 ± 8.7 44.1 ± 9.0 42.5 ± 7.9 NA
Median (min, max) 48.3 (33, 24) 41.7 (24, 57) 44.9 (24, 68) 42.3 (27, 54)
PROMIS Global Mental Health (adult) (T-score)c
Mean ± SD NA NA 53.6 ± 9.9 51.4 ± 8.5 52.6 ± 9.3
Median (min, max) 53.3 (28, 68) 53.3 (39, 68) 53.3 (28, 68)
Total body HO volume, excluding head (mm3)
Mean ± SD 61,951 ± 75,221 159,303 ± 161,779 380,751 ± 363,142 651,913 ± 674,454 324,631 ± 440,977
Median (min, max) 21,692 (0, 224,019) 130,509 (0, 828,262) 258,543 (0, 1,504,849) 481,524 (48,844, 2,833,946) 173,536 (0, 2,833,946)
Number of regions with HOd
Mean ± SD 3.1 ± 2.6 5.1 ± 2.7 7.4 ± 3.4 8.8 ± 3.7 6.4 ± 3.7
Median (min, max) 4.0 (0, 7) 5.0 (0, 14) 8.0 (0, 13) 8.5 (3, 14) 6.0 (0, 14)
aCAJIS assessed range of motion across 12 joints (left and right shoulders, elbows, wrists, hips, knees, and ankles) and three body regions (jaw, cervical spine
[neck], and thoraco-lumbar spine). Each noted as: 0 = uninvolved; 1 = partially involved; 2 = completely ankylosed. Total scores range from 0 to 30 with higher
scores indicating more severe limitations in mobility
bFOP-PFQ used transformed scores expressed as a percentage of the worst possible score. Lower percentages indicate better functioning; higher percentages
indicate worse functioning
cDistributions standardized such that a T-score of 50 (SD of 10) represents the average for the United States general population. Higher T-scores indicate better
physical/mental health
dFifteen possible regions (neck, lower spine/abdomen, upper spine/chest; and both shoulders, elbows, wrists, hips, knees, and ankles)
Abbreviations: CAJIS = Cumulative Analogue Joint Involvement Scale, HO = heterotopic ossification, max =maximum, min =minimum, FOP-PFQ = Fibrodysplasia
Ossificans Progressiva-Patient Function Questionnaire, NA = not applicable, PROMIS = Patient-Reported Outcome Measure Information System, SD = standard
deviation, Yrs = years
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(Fig. 2) and number of body regions with HO (Additional
file 1: Figure S1), indicating that HO increases as subjects
age. The average estimated increase in total HO volume
was 25,574 (95% CI: 18445–32,704) mm3 per year of age;the average increase in the number of affected body regions
was 0.22 (95% CI: 0.16–0.28) regions per year of age.
A visual representation of quantity of HO is shown in
the reconstructed WBCT scans from three representa-
tive NHS subjects of different ages (Fig. 3).
Fig. 1 Correlation between Subject Age and Measures of Functional Disability. Correlation analysis of CAJIS Total Score and age (top) and FOP-
PFQ Percent Total Score and age (bottom) in subjects with FOP. Correlation assessed using linear regression with baseline age as a covariate
Pignolo et al. Orphanet Journal of Rare Diseases           (2019) 14:98 Page 6 of 11HO burden correlates with clinical outcome measures
There was a moderate correlation between the volume
of HO and CAJIS (r = 0.57, Fig. 4), and a strong correl-
ation between the total number of body regions with
HO and CAJIS (r = 0.72, Additional file 1: Figure S1).
The correlations between the volume of HO and the
FOP-PFQ (r = 0.52, Fig. 4), and between the total num-
ber of body regions with HO and the FOP-PFQ (r =
0.69, Additional file 2: Figure S2) were similar. These
correlations indicate that HO substantially contributes
to the functional limitations and disability that patients
with FOP experience.
The CAJIS and FOP-PFQ are also strongly correlated
with each other (r = 0.71, p < 0.0001; Fig. 5) indicatingthat objective worsening in physical disability as assessed
by the investigator closely align with subjective patient
reports of functional impairment.
Discussion
The challenges for the development of therapeutics to
treat rare diseases include the limited number of patients
available for study, the difficulty of demonstrating statis-
tical significance with small samples, variability and
uncertainty about disease progression and clinical out-
comes, and the lack of established endpoints and vali-
dated instruments with which to measure progression
[17]. Comprehensive natural history studies such as this
one, when conducted in a prospective and systematic
Fig. 2 Correlation between Subject Age and HO Volume. Correlation analysis of total body volume of HO and age in subjects with FOP.
Correlation assessed using linear regression with baseline age as a covariate
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identifying clinically meaningful and sensitive endpoints
with which to assess potential disease-modifying agents.
In this international cohort of 114 subjects with FOP
(representing approximately 13% of the known world-wide
population of patients) [3], disease characteristics such as
FOP onset and flare-up frequency, as well as the age andFig. 3 Whole Body Computed Tomography Images from Representative Susex of the sample studied, were consistent with earlier
retrospective studies that obtained patient information
through survey and chart reviews [9, 18], mailed question-
naires [10], or anecdotal reports [12]. The flare-up findings
were also similar to those reported in a 78-question
flare-up survey of 500 FOP patients from 45 countries [8].
Given the size and composition of the NHS sample, andbjects
Fig. 4 Correlation between Total Body Volume of HO and Measures of Functional Disability. Correlation analysis of CAJIS Total Score and volume
of total body HO (top) and FOP-PFQ Percent Total Score and volume of total body HO (bottom) in subjects with FOP. Correlation assessed using
linear regression with baseline age as a covariate
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tailed and prospective results from this NHS are likely to
be representative of the FOP population worldwide.
Unlike earlier studies, a number of bone/cartilage,
angiogenesis, and inflammation biomarkers were assessed
at baseline. These will be followed long-term to determine
whether any are predictive of FOP disease progression.
Subject age was significantly correlated with the CAJIS
and the FOP-PFQ, suggesting that these instruments can
measure the long-term progression of mobility and func-
tional limitations as assessed by the physician and the
patient. The small estimated average increases per year
of 0.47 units for the CAJIS (similar to the estimated an-
nual change of 0.5 units observed by Kaplan, et al) [13]and 1.2% for the FOP-PFQ indicate that a conclusive
treatment benefit may not be demonstrable with either in-
strument over a 1- to 2-year timeframe of a typical clinical
study. Evidence from the literature and clinician experi-
ence indicate that recurrent and cumulative episodes of
HO formation, the pathognomonic feature of FOP, begin
in childhood and lead to increasing disability and func-
tional limitations over time. This is consistent with the
significant correlations observed between the total body
burden of HO (ie, volume of HO and the number of body
regions with HO) and age. These results imply that poten-
tial treatments should target the pediatric population in
order to prevent and/or minimize the irreversible disabil-
ity that occurs as patients age.
Fig. 5 Correlation between CAJIS and FOP-PFQ. Correlation analysis of CAJIS Total Score and FOP-PFQ Percent Total Score in subjects with FOP.
Correlation assessed using linear regression with baseline age as a covariate
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25,574 mm3/year suggests that new HO is an endpoint
that will be measurable over the relative short-term
course of a clinical study. The correlations between the
total body burden of HO and the loss of movement (as
assessed by range of motion across 15 different body
regions in the CAJIS) and worsening functional impair-
ment (as measured by the disease-specific FOP-PFQ)
strongly suggest that HO is a clinically meaningful end-
point. As the number of regions with HO increases and/
or the volume of HO increases, there is a commensurate
decrease in mobility, including complete ankyloses of
joints and increasing functional impairment over time. It
should be noted that some subjects have a high degree
of immobility (as assessed by CAJIS) or physical dys-
function (as assessed by the FOP-PFQ) but little measur-
able HO (Fig. 4). This may be due to small amounts of
HO that are below the level of detection of the WBCT
scans; the specific location of the HO that is impeding
joint movement; or other factors such as congenital joint
malformations or severe degenerative joint disease that
may also contribute to loss of movement and function in
a small percentage of subjects [19]. In addition, the vari-
ability of HO volume observed at baseline across the age
groups will further challenge the investigation of poten-
tial therapeutics in FOP.
While the cross-sectional analyses of the baseline data
from this NHS adds to the clinical perspective on FOP
by quantitatively estimating the rate of progression of
bone deposition and change in functional impairment
over time, the results must be confirmed longitudinally.
One of the objectives of the NHS is to obtain such
long-term data on disease progression over 36 months.
Thus, the assessments performed at baseline are beingrepeated annually and the reported estimated changes
will be corroborated with the actual changes observed
over time. Another limitation is that the NHS only en-
rolled patients with confirmed R206H mutation in the
ACVR1 gene. However, this mutation is present in 97%
of patients with FOP, and few patients have other
FOP-causing mutations in this gene [20, 21].
Conclusions
The baseline data obtained in this NHS are believed to
be representative of the world-wide FOP population.
These data contribute to our understanding of FOP by
characterizing the cross-sectional changes in physical
and functional impairment over the course of the disease
and emphasizing the importance of HO as a substantial
cause of morbidity. In addition, the results provide a ra-
tionale for the selection of endpoints that may be uti-
lized in clinical studies of potential disease-modifying
therapeutics in FOP. In particular, the total body burden
of HO as assessed by WBCT as a clinically meaningful
outcome measure is sufficiently sensitive to document
estimated disease progression and treatment effects over
1–2 years. However, this needs to be verified in ongoing
longitudinal studies in FOP patients. A therapeutic that
reduces, relative to untreated subjects, the number of
body regions with new HO, and/or decreases the forma-
tion of new HO volume, should change disease trajec-
tory and prolong patients’ functional independence.
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